MLXIPL and metabolic dysfunction-associated steatotic liver disease: In our study, the findings claimed that these compounds could be the potential therapeutic candidates for glucose-dependent carbohydrate-signaling gene regulator protein named ChREBP mediated NAFLD and T2DM.